intercepted in middleware. In May 2008, LAS (Laboratory Automation System) was installed in our laboratory. After two years of operation trials, LAS had taken the place of most of the manual efforts. In 2010, the utilization of middleware in an autoverification system was planned. In order to validate whether the verification rules could actually be implemented and meet our requirements, a validation and management mechanism based on a CAP checklist and the CLSI guideline (4, 8, and 9) was established. This manuscript gives a detailed description of the entire validation and management process, and also an evaluation of the benefits brought by the autoverification system to the laboratory.
Materials and Methods

COLLECTION OF PATIENT TEST RESULTS
To define the range of the limit check and the delta check for each test item, 569,001 test results were collected in December 2008. These data were arranged by size, and the distribution percentages of the limit check and the delta check were calculated. These values were then used as the basis for establishing and adjusting the limit check and the delta check of each test item. Also, in order to validate the practicality of the check rules in the autoverification system: (1) 105,164 patient test results were collected for verification of the check rules and their correctness in the autoverification system; (2) 830,233 test results, including 139,650 requisition sheets, were collected for calculation of the autoverification percentage of all items; and (3) 25,526 test reports were collected for probing into the causes of manual verification (MV) so as to obtain the true positivity rate and the false positivity rate of the check rules in the autoverification system.
CONSTRUCTION OF INFORMATION TRANSFER SYSTEM
Both the computer algorithm and the technical data base of the autoverification system were built in middleware (DM2; provided by Beckman Coulter Inc.). The construction of the information transfer system is shown in Fig. 1 . With DM2 as the core center, LIS sends the test orders and patient information to three Beckman Coulter DxC800 biochemical analyzers, two DxI800 immunoassay analyzers and an automated track system (PrepLink, from Beckman Coulter Inc.). The test results from these five instruments are sent back to LIS after verification in DM2; LIS then sends the test reports to HIS (Hospital Information System).
COMPUTER ALGORITHM OF AUTOVERIFICATION PROCESS
Based on the reference methods of the manual check which was regularly used in the past and the CLSI Auto10-A guideline, the critical value check, limit check, delta check, and consistence check were selected for the verification process (Fig. 2) , in addition to patient information and an instrument warning flag.
The precondition for using the autoverification system was that the QC results had to fall within the laboratory's acceptable limit. Together with test results released from the instruments, patient information and the sample condition were entered into DM2 for verification. The order of validation was the critical value check, followed by the limit check, delta check and, finally, the consistency check. If the results passed the critical value check but failed the limit check, the delta check was applied, by which the current data were compared with previous data to determine the differences. When the degree of difference fell within the limit of delta check acceptability, a consistency check followed. Test results passing the above check rules were regarded as AV (autoverified) reports, while results which failed any of the above rules were intercepted as MV (manually verified) reports. There are various reasons why checks fail and thus require MV results; hence, medical technologists must make professional judgments based on their experience. When previous data were used for delta check comparisons the stipulation was that they were to be no older than 7 days.
CONSTRUCTION OF VERIFICATION RULES
The purpose of using autoverification was to produce real time and more accurate test reports with computer verification. Therefore, the infrastructure of the autoverification rules was constructed so as to increase the precision and efficiency of the data checks (10) . The verification rules included a limit check, delta check and consistency check. 569,001 test results were collected in Dec. 2008 as the basis for constructing the verification rules. The principles for constructing the verification rules were as follows:
Limit Check: Data that did not fall within the analytical measurement range (AMR) were considered invalid. For a wide AMR, the acceptable range for the limit check was determined using a distribution interval of patient data of between 2% and 98%. For instance, 2~98% of the 14,239 test results of glucose concentration were within the range of 3.6~20.5 mmol/L, while the AMR for the glucose test was 0.2~33.3 mmol/L; 3.6~20.5 mmol/L was thus established as the limit check interval of glucose when the verification rule was applied. The limit check intervals of all 76 items were constructed using the same principle.
Delta Check: Opinions on the scope of acceptability of the delta check are not consistent.
False positive rates rise when the acceptable range is stringent, whereas a high number of false negatives can be expected from the opposite (11, 12) . Historical delta check data were analyzed, and a relevant difference was assigned as the acceptable range according to the by 50%; (e) there was no delta check for the C-reactive protein (CRP) test when the test value was lower than 8 mg/L, and the difference was 100% when the CRP test value was higher than 8mg/L; and (f) the difference with the previous result was 200% for test results lower than 0.5 ug/L, and 50% for test results above 0.5 ug/L for Troponin I.
Critical Value Check:
As it has been utilized in operation, the critical value bulletined in our hospital was followed.
Consistence Check: As the medical procedures for acute diseases rapidly change and the clinical test results fluctuate, it was difficult to perform a consistency check on each item, and only portions of the test items were established based on practical and clinical diagnostic criteria. For example, if the test result for thyroid stimulating hormone (TSH) was lower than 0.3 mIU/L and free thyroxine (FT4) was lower than 18.1 pmol/L, the report was intercepted as an MV report. In addition, at least 30 consistence-check rules were used in the system.
VALIDATION METHODS
To validate whether or not the verification rules and their settings in DM2 were able to meet our requirements and could actually be executed, electronic simulated data and special sample validation methods were established as follows:
Electronic simulated data validation: In order to support the validity of the limit check, delta check and consistency check, 25 entries of simulated data were created on simulation software built in DM2. Of these,13 data entries fell outside the acceptable range in the limit check, delta check or critical value check, and 12 data entries did not fulfill the consistency check rules or other special rules (data not shown). Through these check rules in DM2, the validation procedure was shown to have a satisfactory performance and to fulfill the necessary requirements.
Special sample validation: Special samples included abnormal proficiency test samples and more than 20 patient samples. Most of the test results fell outside the acceptable range of the limit check and the critical value check .These test results of the special samples were selected to validate the autoverification system's functionality and the reliability of the reports.
Results
LABORATORY TRIAL RUN OF ACTUAL PATIENT TEST RESULTS
According to the CLSI Auto10-A guideline (4), an autoverification system must be validated using actual patient results upon startup. A total of 105,164 test results from August 18 to August 26, 2010 were collected and accessed in the autoverification system to verify the results. The failing and passing rates of the delta checks and the limit checks were then computed, and the results are shown in Table 1 .
As shown in of the 76 test items, the results showed that 62 test items had a passing rate higher than 90% , 9 had a passing rate between 81% and 90%, 3 were between 70% and 80%, and 2 test items were lower than 70% (Fig. 4) .
CAUSE ANALYSIS OF MV TEST REPORTS
To understand the causes necessitating the requirement of manual intervention and, thus, MV data, a total of 25,526 patient reports were collected, with 4,903 reports being classified as MV. The causes of MV reports were analyzed, and the results are shown in Table 2 . Of these MV reports, 41 reports (0.8%) had remarkably abnormal data, which may have been due to sample contamination or anticoagulant interference. Another 300 MV test reports (6.1%)
were marked with error flags from the analyzer: the data were questionable and all were intercepted for further confirmation. Another 4562 MV test reports (93.1%) were classified as acceptable MV data, since they were released without the need of any modification in the original test results after consultation with a clinician. Hence, it could be estimated that the true positivity rate of the intercepted reports was 6.9%.
Discussion
In the given validation of the check rules for the test reports, patient test results were used as the main framework of the validation (see Table 1 ), as their representation of the actual patient results spanned the ranges acceptable for most rules of validation. However, some of the test results were found to be exceptionally abnormal and could not be reported by the autoverification system; as well, such samples were not easily identified in a short period of time. For example: albumin>total protein, Creatine Kinase-MB>Creatine Kinase. In order to validate these rules or cases, we used simulation software in the middleware to validate whether the verification rules and process were well implemented. Our results demonstrated that the rules and workflow designed were able to be correctly executed. Table 1 and Figure   3 show that the autoverification system designed in this study yielded an average passing rate of 95% for all test results, and a higher AV rate, as compared to previously published data, of 73% (13). This could be because different laboratories have different acceptable ranges for the limit check and the delta check for each test item. For example, the range of the delta check was set between 5% and 200% in our laboratory, while others may adopt 20% to 30%
for their acceptable range (13) . Furthermore, as shown in Fig. 4 , two test items, ethanol and human chorionic gonadotropin (hCG), were accepted via AV with a passing rate lower than 70% (27% and 68%, respectively). It was concluded that the legal cutoff of the alcohol concentration for illegal drunk driving in Taiwan was 10.8 mmol/L, and requests for blood alcohol tests always involved traffic issues. For this reason, the blood alcohol concentration was usually higher than the legal ethanol concentration cutoff. As the reports might be used for legal purposes, the removal of such test items and the application of manual checks to all ethanol-related reports was considered. A low AV passing rate of hCG was correlated with the analytic measurement range of the analyzer, which was 0.5~1000 IU/L for hCG.. Pregnant women usually have an hCG level higher than AMR. Although the instrument might automatically dilute the samples and mark it with a dilution flag, the processing of the result still required manual intervention.
One of the most important functions in the autoverification system was to hold the samples with errors reports. Table 2 shows that of the 25,526 patient reports, 41 were classified as having remarkably abnormal data and requiring interception or rejection. Further investigation revealed that the abnormalities in the data were due to serious hemolysis during blood sampling (test items such as K, LD, AST, etc.), EDTA contamination (test items K and CA failed the limit check and the delta check), and severe lipemia or insufficient samples.
Also, 6.9% of the MV data was rendered non-reportable due to an error flag marked by the instrument. The remaining 4,562 (93.1%) reports were classified as acceptable MV data, and the required manual intervention was identified to be caused by changes during medical procedure. These test results were reported after a brief communication with a clinician.
These samples were re-tested, and the results were consistent with the previous results. When compiling the statistics according to the panel tests in the test requisition sheets, the AV passing rate was 81.5% at the current stage, which greatly alleviated the burden in report verification.
The stability of the performance of the automated analyzers now in use is relatively better.
With the aid of the barcode system, the error rate in the laboratory is greatly reduced. The function of an autoverification system is not only to detect errors in the test results, but also, by its application, to improve patient clinical care. For example, results in the delta check falling outside of the acceptable range could imply a significant change in the patient's condition. In such cases, the laboratory would inform the physician so the patient can receive appropriate treatment.
Quality control (QC) results should confirm if an item falls within the acceptable range before the autoverification system starts; otherwise the verification procedure should cease.
At present, the QC system is not connected with the autoverification system of the middleware; hence, manual intervention had to be adopted to control the mechanism which determined whether the QC results were acceptable. For this reason, the QC system should be integrated with the autoverification system; then, when QC failure occurs, the autoverification of the given test item will automatically stop.
Most publications describe the autoverification system as a way to shorten TAT in reporting test results and thus reduce the labor burden in the laboratory (13) . However, as different laboratories have different working configurations and workflow, it was estimated that the use of an autoverification system would have an FTE of 3.5 full time employees per year in our laboratory. The TAT of patient reporting was dramatically reduced because we released the AV test reports immediately instead of the previous batch release. However, our experience has suggested that the greatest benefit from the system was the consistency of the Legends for Figures   Fig. 1 : DM2 as the core center of the autoverification system 
